A client is experiencing anaphylactic shock after being stung by a bee. Which medication should the nurse administer first?

Choice A rationale Epinephrine is the most critical medication in the management of anaphylaxis. It is a catecholamine that provides rapid systemic effects to counteract the massive vasodilation and bronchoconstriction triggered by the allergen. By stimulating alpha-adrenergic receptors, it increases peripheral vascular resistance and blood pressure. By stimulating beta-two receptors, it relaxes bronchial smooth muscle. Immediate administration is vital to prevent total respiratory arrest and cardiovascular collapse, making it the highest priority intervention for any nurse caring for a patient with this condition. Choice B rationale Naloxone is a medication designed to reverse the effects of opioids. In the context of a bee sting and anaphylactic shock, the patient is suffering from an overactive immune response, not a drug overdose. Naloxone provides no benefit for airway patency or blood pressure stabilization in an allergic emergency. Using this medication would be a critical error in judgment, wasting precious time that should be spent administering epinephrine to save the patient's life from an impending airway obstruction. Choice C rationale Atropine sulfate is primarily used to increase heart rate in patients with symptomatic bradycardia by inhibiting parasympathetic influence. In anaphylactic shock, the patient often has tachycardia as the body tries to compensate for low blood pressure. Adding atropine would not fix the underlying problem of vascular permeability and smooth muscle contraction in the lungs. It lacks the necessary alpha and beta-agonist properties required to reverse the complex multisystem failure occurring during a severe, life-threatening anaphylactic reaction. Choice D rationale Diphenhydramine is a second-line treatment for anaphylaxis. While it helps mitigate the effects of histamine release, it works too slowly to be the first medication administered in an emergency. It does not possess the ability to cause the rapid vasoconstriction or bronchodilation needed to keep a patient alive during the acute phase of shock. It is typically given after epinephrine has stabilized the patient to help control the remaining skin symptoms and prevent a secondary or protracted allergic response.